The Life Sciences team advised Asher Biotherapeutics in the closing of its Series B financing, which raised $108 million. The financing was led by Wellington Management Company LLP, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors. Proceeds from this financing will enable Asher Bio to fund its lead cis-targeted immunotherapy, AB248, through clinical proof-of-concept, while advancing a second program through investigational new drug (IND)-enabling studies and continuing to invest in its cis-targeting platform.
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. The company’s cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco.
The Goodwin team included Sam Zucker, Stephanie Richards, Maria Jose Dobles Madrigal, and Vanessa Quiban-Tolentino.
For additional details on the financing round, please read the press release.